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50a Sunday, February 3, 2013destabilizing conditions, WT myoc-OLF has a distinct non-native structure ca-
pable of forming amyloid fibrils. In the case of disease-causing myocilin vari-
ants, this non-native structure is accessible under physiological conditions,
leading to accelerated fibril growth. Building on the hypothesis that partial un-
folding of myoc-OLF is necessary for fibril growth, this study also investigates
the structural and biophysical effects of adding stabilizing agents, such as os-
molytes and Ca2þ, to the myoc-OLF domain as a strategy to prevent myoc-
OLF amyloid aggregation. The results of this study suggest a novel protein-
based hypothesis for glaucoma pathogenesis and the need for further testing
in a clinical setting.
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Somatostatin-14 (SST-14) is a small cyclic peptide hormone secreted by
hypothalamus, one of the well-known functions of which in the body is growth
hormone inhibition. SST-14 has previously been reported to spontaneously
self-assemble in water containing 150 mM NaCl into amyloid-like nanofibrils.
Recently, it was shown that SST-14 forms amyloid in presence of glycosami-
noglycan heparin at secretory granule relevant conditions. However, the path-
way of its amyloid formation in not understood yet. In the present work, we
studied the mechanism of SST-14 amyloid formation in vitro as well as in
silico, in the presence and absence of heparin. Our in vitro data suggests that
SST-14 in presence of heparin, transforms from its monomeric ‘random coil’
conformation to a secondary structure representing amyloid, via a ‘helix-rich
intermediate. It was observed in this study that SST-14 adopts a ‘nucleation-de-
pendent polymerization’ mechanism of amyloid formation. We also studied the
disulphide bond reduced ‘non-cyclic’ SST-14 (ncSST) form for amyloid forma-
tion, and observed that ncSST formed amyloid fibrils instantaneously in pres-
ence of heparin compared to the cyclic form. Furthermore, the ncSST fibrils
were observed to possess higher conformational and thermal stability relative
to the cyclic SST-14 fibrils.
Using all-atom molecular dynamics simulations, we studied molecular interac-
tions among SST-14 peptides in the presence and absence of heparin. Our in
silico results suggest that heparin induces aggregation of SST-14 by increasing
local concentration of the peptides and promotes interpeptide contacts and sec-
ondary structure transformation in the peptides. Overall, this study offers the
mechanism of somatostatin-14 oligomerization and amyloid formation, which
has substantial value in understanding its storage within secretory granules.
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It is widely recognized that peptide assembly into fibrils (or amyloids) sensi-
tively responds to conditions set by myriad cellular solutes. These cosolutes in-
clude two important classes: macromolecular crowders and compatible
osmolytes. In effort to resolve the effect by which these cosolutes control pep-
tide self-assembly, we have recently found that addition of macromolecular
PEG only slightly affects fibril formation of a model peptide in vitro. Polyol
osmolytes, in contrast, lengthen the lag time for aggregation, and lead to larger
fibril mass at equilibrium. Model calculations suggest that all cosolutes simi-
larly lengthen the time required for nucleation, possibly due to their excluded
volume effect. However, PEGs may in addition promote fibril fragmentation,
leading to lag times that are overall almost unvaried. Moreover, polyols effec-
tively slow the monomer-fibril detachment rates, thereby favoring additional
fibril formation. Preliminary results from coarse-grained molecular dynamics
allow us to follow the first steps of protein assembly and nucleation. Input
from experimental solvation thermodynamics of a model peptide are used to
calibrate our simulations, and to test the effect of cosolutes on peptide assembly
into proto-fibrils. Our analysis provides first hints that cosolutes act not only by
changing association or dissociation rates of peptide self assembly, but poten-
tially also by directing the formation of fibrils of varied morphologies with dif-
ferent mechanical properties. Importantly, hydration interactions are suggested
as an integral component that directs this process. Although additional exper-
iments are needed to unambiguously resolve the action of excluded cosolutes
on amyloid formation, it is becoming clear that these compounds are important
to consider in the search for ways to modulate fibril formation.
1. S. Sukenik, R. Politi, L. Ziserman, D. Danino, A. Friedler, and D. Harries,
PloS one, 2011, 6, e15608.
2. S. Sukenik and D. Harries, Prion, 2012, 6, 26-31.257-Pos Board B26
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A class of ultrasmall tri to hepta peptides self-assemble into hydrogels, due to
their characteristic sequence motif - an aliphatic amino acid tail of decreasing
hydrophobicity capped by a polar head. These peptides organize themselves to
supramolecular scaffolds of long helical fibers that extend to the mm-range.
During self-assembly, these peptides form amyloid aggregates via unexpected
a-helical intermediates, with the trimer as the shortest ever reported sequence
with a-helical propensities. Circular dichroism and X-ray diffraction confirmed
conformational changes terminating in thermo-stable b-type structures. Molec-
ular dynamics simulations of peptide behavior in water revealed monomer
antiparallel pairing and stably condensed coiled fibers. The assembled macro-
structures are biocompatible and non-toxic. Their high mechanical strength
can be tuned by adjusting salt and pH, paving the way for applications from in-
jectable therapies to repair and replacement of damaged tissues. In particular,
their biocompatibility towards a variety of human and othermammalian primary
cells, qualifies them for future applications
in tissue engineering andmedical regenera-
tive therapy. The ultrasmall size and the dy-
namic facile assembly process make this
peptide class an excellent model system
for studying the mechanism of amyloido-
genesis, its evolution and pathogenicity.258-Pos Board B27
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Many soluble proteins self-assemble into fibrillar, b-sheet rich, stable aggre-
gates that are each associated with a particular disease. It is thought that peptide
segments within these proteins form the core amyloidogenic region that drives
fibrillization of the protein, and it has been shown that these segments, alone,
form fibrillar structures. Here, we seek to determine the nature of fiber nucle-
ation of these peptides. Amyloid fibers can be nucleated via a fiber-
dependent pathway in which additional protein adds onto the ends and extends
existing fibers. However, it is hypothesized that the walls of existing fibers can
also nucleate amyloid fibers in a peptide-specific manner using the solvent-
exposed side chains as a template. Conditions necessary for aggregation have
been investigated for a set of amyloidogenic peptides. We have found that ag-
gregation depends on peptide and salt concentration and occurs on the time-
scale of hours. We have also employed a novel approach for presenting an
amyloid fiber wall without presenting fiber ends. These studies illustrate the
conditions and geometry important for novel nucleation mechanisms of fiber
formation.
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Surface layer (S-layer) proteins form a highly ordered crystalline, yet porous,
layer on the outermost cell surface of most species of bacteria and archaea.
S-layers not only provide the cell a layer for protection, they are postulated
to mediate several functions such as cell adhesion, drug resistance and provid-
ing a scaffold for mineralization. Thus, S-layers provide a robust in vitro model
system to test our understanding of the dynamics of self-assembly pathways, as
well as a biological scaffold for hierarchical assembly of nano-materials. The
SbpA protein from Lysinibacillus sphaericus is a well characterized S-layer
protein that forms Ca2þ dependent, 2D crystals in solution with square symme-
try. Here we use ensemble techniques to study the self-assembly process in so-
lution. We use light scattering to follow assembly kinetics and determine
a phase a diagram for crystallization; moreover we use electron microscopy
and SAXS to confirm that SbpA forms large crystalline sheets in solution, de-
tectable by our assay. Surprisingly, we find that while SbpA requires a minimal
amount of Ca2þ to crystallize, excess divalent ions in solution inhibit interac-
tion between subunits and thus self-assembly. In addition, we find that the crys-
tallization of SbpA does not require the formation of a nucleus, and that all the
steps for self-assembly are energetically favorable. We propose a model in
Sunday, February 3, 2013 51awhich SbpA monomers that lack significant tertiary structure aggregate rapidly
in solution to form dense protein clusters, which then order into crystalline
sheets.
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The aggregation of amyloidogenic proteins is infamous for being highly cha-
otic, with small variations in conditions leading to large changes in aggregation
rates. We present experimental evidence that the origin of this phenomenom for
a broad variety of amyloidogneic oligomers is related to the critical concentra-
tion for the formation of particular type of prefibrillar oligomer. Using chemical
probes and real time solution NMR, we show that oligomers of this type revers-
ibly form at sharply defined critical concentrations and temperatures in a man-
ner similar to a phase transition. Similarly, the kinetics of fiber formation also
show strong non-linearity near these critical points. For some amyloidogenic
proteins such as IAPP, the pathway of amyloid formation switches as the crit-
ical point is approached, with aggregation initiating at different regions of the
protein above and below the critical point. We also show that part of the effect
of some inhibitors on amyloid aggregation is to abolish or shift the critical con-
centration, and map the interface between monomeric IAPP and Ab and these
aggregates.
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The aggregation mechanism of the prion protein is known to be complex. It is
highly heterogeneous since multiple oligomeric as well as fibrillar structures
are being populated. It is essential to understand the disease-associated assem-
bly of prion protein monomers into high-molecular-weight polymers in mech-
anistic terms in order to be able to develop tailored therapeutic approaches.
This requires following the aggregation process in detail on the molecular level.
Kinetic methods are especially suited in this respect as the desired mechanistic
information is contained in the kinetic data.
We have investigated the aggregation of the wildtype murine prion protein at
atomic resolution using kinetic two-dimensional (2D) NMR spectroscopy.
We have found amino-acid-specific differences for the decrease in the mono-
mer concentration thereby delineating heterogeneity in the aggregation kinet-
ics. SDS PAGE shows that oligomers of differing size are being formed
which are characterized by extremely high stability. Furthermore, Congo red
dye binding experiments demonstrate that the prion protein assembles into
amyloid-like fibrils. By combining the data acquired by using different methods
we derive a model for the aggregation mechanism of the prion protein. In ad-
dition, we will also present kinetic 2D NMR data on the aggregation of disease-
associated single point mutants of the prion protein such as V180I and E200K
and discuss which aggregation sub-steps are affected by the mutations.
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g-Synuclein is a small intrinsically disordered protein of unknown function that
is usually found in the peripheral nervous system. Phospholipase b2 (PLCb2) is
an important component of the G-protein signaling pathway and its activation
leads to calcium release in cells. These two proteins are both overexpressed in
late stage breast cancer but not in early stage (Stage I and II) or in healthy breast
tissues. We have previously shown that g-synuclein binds strongly to PLCb2
both in-vivo and in-vitro, as demonstrated by immunoprecipitation, immuno-
fluorescence and binding assays. Here, we show that knocking down the ex-
pression of g-synuclein using siRNA, results in a concomitant reduction in
the expression of PLCb2. Here, we also find that reducing the level of g-syn-
uclein in MDA MB 231 cells (which mimics stage 4 breast cancer) causes sig-
nificant changes in cell morphology that indicate a reversion to healthy breast
cell phenotype. Additionally, such reduction of g-synuclein in MDA MB 231cells results in a stronger and faster calcium release in response to G protein
stimulation, corroborating our previous work showing that the binding of g-
synuclein to PLCb2 reduces its activity. We are currently investigating whether
g-synuclein promotes cell proliferation, migration and invasion through its as-
sociation with PLCb2. A peptide inhibitor of the g-synuclein – PLCb2 complex
is presently being tested.
This work was supported by NIH GM053132
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Aggregation of the protein a-synuclein has been associated with Parkinson’s
disease. Here we present a novel way of looking into the aggregation problem,
where we claim that aggregation is correlated with the intramolecular diffusion
dynamics of the polypeptide chain. We hypothesize that the first step of aggre-
gation of disordered proteins, such as a-synuclein, is controlled by the rate of its
backbone reconfiguration. When reconfiguration is fast, bimolecular associa-
tion is not stable, but as reconfiguration slows, association is more stable and
subsequent aggregation is faster. We have tested this hypothesis by investigat-
ing the effects of mutation on the diffusion dynamics of a-synuclein and our
experiments show that mutations enhance or inhibit aggregation based on
how the rate of reconfiguration changes. We have also tested the effects of cer-
tain aggregation inhibitors on a-synuclein. Existing drug screening methods of
such inhibitors are based on their ability to prevent fibrillization as opposed to
initial steps of aggregation. Since our approach probes into the diffusion dy-
namics of the polypeptide chain, it allows us to investigate the inhibitor’s ef-
fects on earlier steps of aggregation, which is believed to be more related to
pathogenesis than the later stages.
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The neural protein a-synuclein (aS) is known to be involved in the develop-
ment of Parkinson’s disease, but specifics about its structure and function re-
main to be determined. aS is intrinsically disordered in solution; however,
upon interacting with lipid membranes, the N-terminus forms an amphipathic
helical structure along the membrane interface while the C-terminus remains
unstructured in solution. A thiocyanate probe group has been covalently at-
tached to a number of single-cysteine variants of aS, and IR signals were ob-
tained to investigate the environment and local dynamics of the N-terminal
segment of aS. The frequency of the aliphatic CN absorption band of the probe
group in the IR spectrum is sensitive to the degree of hydration of the probe,
indicating its orientation with respect to the bilayer, while the bandwidth of
the CN stretching absorption is sensitive to the ps solvent dynamics surround-
ing the probe and can report on local rigidification of the structure. Spectra of
aS in a number of different lipid systems have provided new information re-
garding the dynamics and structure of the lipid-bound conformation, including
direct evidence for a partially-bound structure in which only the beginning of
the N-terminus is associated with the lipid membrane.
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Aggregation of the neuronal protein alpha-synuclein (aS) is implicated in the
pathology of Parkinson’s disease (PD). The causative role of aS in disease is
further supported by rare mutations in or gene multiplications of aS that are re-
sponsible for early-onset PD. While the link between aS and PD is well estab-
lished, the physiological roles of aS are not well-understood. A likely function
has been suggested in regulation of synaptic vesicle fusion and maintenance of
the synaptic vesicle pool, with recent work indicating a direct interaction be-
tween aS and SNARE proteins. Here, using an in vitro fusion assay, we inves-
tigate the mechanism by which aS modulates SNARE-mediated vesicle fusion.
We find that aS inhibits fusion in a manner that correlates with its affinity for
the lipid bilayer. Moreover, we do not detect interactions between aS and
SNARE proteins in a variety of assays. Although we cannot completely elim-
inate the possibility of weak or transient interactions with SNARE proteins, our
results suggest that aS inhibits fusion through its interaction with the lipid
membrane rather than SNARE components.
